Information Provided By: 
Fly News Breaks for September 28, 2017
CEMI
Sep 28, 2017 | 11:47 EDT
Benchmark analyst Raymond Myers called Chembio Diagnostics' Emergency Use Authorization clearance from the FDA for the company's rapid point-of-care Zika test an "important regulatory win." He is not adjusting his estimates following the news, but said it makes him much more confident in his "strong" 2018 revenue growth forecast for Chembio. Myers keeps a Speculative Buy rating on the stock.
News For CEMI From the Last 2 Days
There are no results for your query CEMI
